Inclusion Criteria: - Age ≥ 18 years. - Subject has histologically or cytologically confirmed HER2-negative adenocarcinoma of the breast. HER2 status should be determined by an accredited laboratory - Locally advanced or metastatic disease. Locally advanced disease must not be amenable to resection with curative intent. Must have measurable or non measurable disease (but radiologically evaluable) according to RECIST 1.1. - All computer tomography (CT; with contrast) and magnetic resonance imaging (MRI) used to document disease must have been done ≤ 4 weeks before randomization. Bone scans (if clinically indicated) must have been done ≤ 8 weeks prior to randomization - Subjects are resistant to or have failed prior taxane and an anthracycline OR resistant to or have failed prior taxane AND for whom further anthracycline therapy is not indicated. - Treatment failure is defined as: - Documented tumor progression >4 and 12 months after the last dose of therapy when given in the metastatic setting OR - Recurrence > 6 and less than or equal to 12 months of the last taxane or anthracycline dose when given in the adjuvant or neo-adjuvant setting. Note: Subjects who relapse beyond 12 months after the last taxane or anthracycline dose given in the adjuvant, neo-adjuvant, or metastatic setting may be considered eligible for the study provided that further anthracycline therapy and further taxane therapy have both been considered and ruled out due to: - Cumulative dose of anthracycline (240-400 mg/m2 doxorubicin to 300cc-550 mg/m2 doxorubicin equivalents) OR - Intolerance before enrollment in this study as defined as: - Anthracycline - (1) cardiotoxicity regardless of dose; or (2) severe/life-threatening toxicity (eg, hypersensitivity) during prior treatment - Taxane - (1) severe/life-threatening toxicity (eg, fatigue, hypersensitivity) during prior treatment; or (2) unacceptable peripheral neuropathy following prior treatment - Subject must have received no more than one chemotherapy treatment for metastatic disease. - Prior hormonal therapy for locally advanced or metastatic breast cancer is allowed. Subjects who are refractory to hormonal therapy are allowed. - Prior neo-adjuvant or adjuvant chemotherapy is allowed. - Subject must have discontinued prior chemotherapy, prior radiation therapy, or prior hormonal therapy for locally advanced or metastatic disease greater than or equal to 4 weeks (28 days). Start of study treatment is allowed within less than 28 days of the prior therapy provided that 5 half-lives of the prior treatment drug(s) have elapsed before start of treatment. - Adequate bone marrow, liver, and renal function within 7 days prior to randomization as assessed by serum blood tests and all acute toxic effects of any prior treatment have resolved to NCI-CTCAE v4.0 Grade 1 or less at the time of signing the Informed Consent Form (ICF). - Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to randomization. - Subjects (men and women) of childbearing potential must agree to use adequate contraception beginning at the signing of the ICF until at least 30 days after the last dose of study drug. - Subject must be able to swallow and retain oral medication Exclusion Criteria: - HER2-positive breast cancer. - Unknown hormone receptor status (estrogen and progesterone receptor). - Subjects with bilateral breast cancer or a history of two distinct breast cancers are excluded. - Subjects with inflammatory breast carcinoma are excluded - Subjects who have received no prior taxane and anthracycline for the treatment of breast cancer (either in adjuvant, neo-adjuvant or metastatic setting). - Prior use of any licensed or investigational drug that targets VEGF or VEGFR (eg, bevacizumab, brivanib, sunitinib, vatalinib). - Prior use of sorafenib or capecitabine - Subjects considered by the treating investigator to be appropriate candidates for hormonal therapy as current treatment for metastatic breast cancer are excluded. - Subjects with seizure disorder requiring medication - Subjects with active brain metastases or leptomeningeal disease. - Radiation to any measurable target lesions less than or equal to 4 weeks prior to randomization. - Major surgery, open biopsy, or significant traumatic injury 4 weeks before signing the ICF. - Evidence or history of bleeding diathesis or coagulopathy., Uncontrolled hypertension , Active or clinically significant cardiac disease, Subjects with thrombotic, embolic, venous, or arterial events such as cerebrovascular accident (including transient ischemic attacks) within 6 months before randomization - Subject with any pulmonary hemorrhage/bleeding event of NCI-CTCAE v4.0 Grade 3 or higher within 4 weeks before randomization; - Subjects with an infection of NCI-CTCAE v4.0 Grade 2 or higher. - Subjects with a history of human immunodeficiency virus infection or current chronic or active hepatitis B or C infection. - Presence of a non-healing wound, non-healing ulcer, or bone fracture - Subjects who have used strong CYP3A4 inducers (eg, phenytoin, carbamazepine, phenobarbital, St. John's Wort [Hypericum perforatum], dexamethasone at a dose of greater than 16 mg daily, or rifampin [rifampicin], and/or rifabutin) within 28 days before randomization. - Subjects with any previously untreated or concurrent cancer that is distinct in primary site or histology from breast cancer except cervical cancer in-situ, treated basal cell carcinoma, or superficial bladder tumor. Subjects with a history of two distinct breast cancers are excluded - Subjects with a history of dihydopyrimidine dehydrogenase (DHPD) deficiency or severe and unexpected reactions to fluropyrimidine - Women who are pregnant or breast-feeding. - Any condition which, in the investigator's opinion, makes the subject unsuitable for trial participation